Fulgent Genetics, which offers genetic testing for over 7,500 conditions, raised $38 million by offering 4.2 million shares at $9, the low end of the range of $9 to $11. Fulgent originally planned to raise $60 million by offering 4.6 million shares at $12 to $14, but revised its range on Wednesday. The company plans to list on the Nasdaq under the symbol FLGT. Credit Suisse, Piper Jaffray and Raymond James acted as lead managers on the deal....more
Tabula Rasa HealthCare, which provides e-prescription fulfillment and medication risk management services, raised $52 million by offering 4.3 million shares at $12, below the range of $13 to $15. Tabula Rasa HealthCare plans to list on the Nasdaq under the symbol TRHC. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray acted as lead managers on the deal....more
MedEquities Realty Trust, a recently-formed REIT focused on health care properties in Texas and California, raised $239 million by offering 19.9 million shares at $12, the low end of the range of $12 to $14. MedEquities Realty Trust plans to list on the NYSE under the symbol MRT. FBR Capital Markets, J.P. Morgan, Citi and KeyBanc Capital Markets acted as lead managers on the deal....more
Fulgent Genetics, which offers genetic testing for over 7,500 conditions, lowered the proposed deal size for its upcoming IPO on Wednesday.
The Temple City, CA-based company now plans to raise $42 million by offering 4.2 million shares at a price range of $9 to $11. Insiders intend to purchase $11 million worth of shares in the offering. The company had previously filed to offer 4.6 million shares at a range of $12 to $14. At the midpoint of the revised range, Fulgent Genetics will raise 30% less in proceeds than previously anticipated.